[VIRTUAL] Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).

ATX-101 - APIM Therap

Charlotte Rose Lemech; Ganessan Kichenadasse; Jens-Peter Marschner; Kostas Alevizopoulos; Marit Otterlei; Michael Millward

Apr 28, 2021